Max Levitt, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 1211 Cushman St, Fairbanks, AK 99701 Phone: 907-328-0989 Fax: 855-259-0324 |
Tony Nimeh, MD Urology Medicare: May Accept Medicare Assignments Practice Location: 1211 Cushman St, Fairbanks, AK 99701 Phone: 907-328-0989 |
Doug Cho, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 5955 Zeamer Ave, Jber, AK 99506 Phone: 907-580-1240 |
John Whitford Huffer, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 3000 Vintage Blvd Ste 270, Juneau, AK 99801 Phone: 907-586-1450 Fax: 907-500-7395 |
Mr. Gary J Schoenrock, MD Urology Medicare: Medicare Enrolled Practice Location: 3100 Tongass Ave, Ketchikan, AK 99901 Phone: 907-225-5237 Fax: 907-228-8496 |
Greg O Lund, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2490 S Woodworth Loop 401, Palmer, AK 99645 Phone: 907-745-9300 Fax: 907-745-9301 |
Dr. Jeff A Simerville, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2490 S Woodworth Loop, Suite 401, Palmer, AK 99645 Phone: 907-745-9300 |
News Archive
Parenting a teenage athlete is a juggling act—monitoring homework, keeping up with practice and training schedules, weeks packed with competitions or games. It may seem like a never-ending "to do" list and that yearly sports physical can seems like just one more thing in a busy parent's life. But the quickest way of checking if off the list could be detrimental to a teen's health.
Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.
A College of Osteopathic Medicine student has been awarded the prestigious Ruth L. Kirschstein National Research Service Award from the National Institutes of Health for his work on identifying the causes leading to cleft palate.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today the results of a clinical trial of its investigational Fluzone Quadrivalent (Influenza Virus Vaccine) compared to the currently licensed Fluzone (Influenza Virus Vaccine). Data from the Phase II trial assessing the immunogenicity and safety of the investigational quadrivalent vaccine were presented at the 48th Annual Meeting of the Infectious Diseases Society of America in Vancouver, British Columbia.
› Verified 9 days ago